KPV: The Tripeptide That Kept the Brake, Not the Dial

The short version

KPV is a very small peptide — just three amino acids (lysine, proline, valine) — clipped from the tail end of a much larger hormone, alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is best known for controlling skin pigment, but KPV keeps only its anti-inflammatory activity, not the pigment-changing one. In lab and animal studies, KPV calms inflammation by damping down the same NF-kB signaling switch that drives much of the body's inflammatory response.

Every KPV study on this page is either a cell-culture experiment or a mouse study of colitis (inflammatory bowel disease). There are no published human clinical trials of KPV. Most of the recent research effort is not about whether KPV works in a dish or a mouse — it clearly can — but about formulation: KPV is a small, fragile peptide that gets broken down quickly, so researchers have spent the last decade building nanoparticles and hydrogels to get it into inflamed gut tissue intact.

This page reports those findings in the models where they were found. No dose is recommended for a person.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), molecular formula C16H30N4O4 — the C-terminal three residues (positions 11-13) of alpha-MSH. Because it is such a short chain, it lacks the receptor-binding architecture that gives full-length alpha-MSH its pigment-related (melanogenic) activity, but it retains the anti-inflammatory signal researchers attribute to the same C-terminal region ^[12].

That small size cuts both ways. KPV is cheap to synthesize and diffuses readily, but it is also a ready target for the body's own peptidases — enzymes that break peptides down — which is why so much of the recent literature is formulation science rather than new biology: hydrogel encapsulation, targeted nanoparticle co-delivery, and hyaluronic-acid functionalization are all attempts to protect KPV long enough for it to reach inflamed tissue intact ^[8][9].

How it works

KPV's anti-inflammatory action centers on two things: how it gets into cells, and what it shuts off once it is there. In the gut, KPV is taken up directly into intestinal epithelial cells through a transporter called PepT1 (SLC15A1), which normally imports small di- and tripeptides from digested food — and which is upregulated in inflamed intestinal tissue, effectively concentrating KPV exactly where it is needed ^[10].

Once inside, nanomolar concentrations of KPV suppress two related inflammatory signaling cascades — NF-kB and the MAP-kinase pathway — and reduce the secretion of pro-inflammatory cytokines including IL-1beta and TNF-alpha ^[10]. Notably, this anti-inflammatory effect does not require the melanocortin receptor MC1R that mediates alpha-MSH's pigment effects: KPV retained its protective activity in MC1R-deficient mice, indicating the anti-inflammatory mechanism runs through a separate pathway from the pigmentary one ^[11].

What the research shows

The foundational mechanistic work is a 2008 study showing nanomolar KPV suppresses NF-kB and MAP-kinase activation and cytokine secretion in human intestinal epithelial cells and Jurkat T cells in vitro, and reduces colitis severity when given orally to mice in two induced-colitis models (DSS and TNBS) ^[10]. A companion 2008 study in a separate colitis model found KPV-treated mice recovered earlier, regained body weight faster, and showed lower colonic inflammatory-cell infiltrate and myeloperoxidase activity (a marker of neutrophil activity) than untreated mice — and that the effect persisted in mice lacking the MC1R receptor, ruling out the pigmentary pathway as the mechanism ^[11].

Since then, the field has moved toward delivery engineering. A 2017 study built hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel for oral delivery, and found this targeted formulation reduced colitis severity, downregulated TNF-alpha, and accelerated mucosal healing more than non-targeted delivery of the same peptide ^[9]. Most recently, a 2024 study went further still, co-assembling KPV with the immunosuppressant drug FK506 into a single PepT1-targeted nanodrug; in mice, this combination improved outcomes in both acute and chronic colitis, restoring gut tight-junction proteins and lowering inflammatory cytokines beyond what either agent achieved alone ^[8]. Taken together, the studies on this desk describe a consistent biological effect — NF-kB/MAPK suppression, reduced colitis severity — paired with an evolving, still-active formulation problem.

Reported effects, cautions & safety

No published human clinical trials of KPV exist, so there is no clinical-trial safety record and no compiled body of community or patient-reported effects to describe here — the entire KPV literature on this desk is in vitro and murine. This site does not manufacture anecdotal reports to fill that gap.

What the record does support are several firm cautions. Because free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics, the formulation work described above — nanoparticles, hydrogels, targeted carriers — exists specifically because the naked peptide does not survive long enough in a biological system to be reliably useful; this remains an open engineering problem, not a solved one. Marketing claims for KPV in gut health, skin, or general anti-inflammatory contexts routinely outrun the evidence, which is mechanistic and preclinical rather than clinical.

Although KPV derives from alpha-MSH, its defining property in the literature is anti-inflammatory action without the parent hormone's pigmentary effect, so claims that treat it as a tanning or pigmentation agent misdescribe it. Reported PMID and DOI errors are common in secondary web sources for KPV; every identifier drawn on for this page was independently re-verified against PubMed and Crossref rather than copied from an aggregator. KPV is sold by chemical suppliers strictly for laboratory research use and holds no approved drug or dietary-supplement status in any major jurisdiction.

Where it fits in Immune & Thymic research

KPV is the locally delivered half of the story on this desk — a peptide with no hormone axis of its own, engineered almost entirely around getting a fragile molecule to a specific inflamed tissue ^[8][9]. Thymulin works the opposite way: a systemic, zinc-dependent hormone whose gene-therapy studies aim at reversing whole-organ disease from a single dose ^[1]. Both converge on the same molecular target — NF-kB signaling ^[3][10] — which is exactly what makes comparing them useful. See the comparison page for the full picture.